Literature DB >> 28591538

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.

Michael Fralick1, Sebastian Schneeweiss1, Elisabetta Patorno1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28591538     DOI： 10.1056/NEJMc1701990

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  70 in total

Review 1.  SGLT2 inhibition and heart failure-current concepts.

Authors:  Joaquim Silva Custodio; Andre Rodrigues Duraes; Marconi Abreu; Natalia Albuquerque Rocha; Leonardo Roever
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

2.  Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.

Authors:  Jenny E Blau; Sri Harsha Tella; Simeon I Taylor; Kristina I Rother
Journal:  Diabetes Metab Res Rev       Date:  2017-09-29       Impact factor: 4.876

3.  Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor.

Authors:  Lydia Zhang; Michael Tamilia
Journal:  CMAJ       Date:  2018-06-25       Impact factor: 8.262

Review 4.  Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.

Authors:  Beatrice C Lupsa; Silvio E Inzucchi
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

Review 5.  Empagliflozin: A Review in Type 2 Diabetes.

Authors:  James E Frampton
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 6.  [Diabetic emergencies : Hypoglycemia, ketoacidotic and hyperglycemic hyperosmolar nonketotic coma].

Authors:  H Kalscheuer; G Serfling; S Schmid; H Lehnert
Journal:  Internist (Berl)       Date:  2017-10       Impact factor: 0.743

7.  SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.

Authors:  Soravis Osataphan; Chiara Macchi; Garima Singhal; Jeremy Chimene-Weiss; Vicencia Sales; Chisayo Kozuka; Jonathan M Dreyfuss; Hui Pan; Yanin Tangcharoenpaisan; Jordan Morningstar; Robert Gerszten; Mary-Elizabeth Patti
Journal:  JCI Insight       Date:  2019-03-07

8.  Have Current Systems of Pharmacovigilance Had Their Day?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2020-04-01

9.  Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.

Authors:  Michael Fralick; Sarah K Chen; Elisabetta Patorno; Seoyoung C Kim
Journal:  Ann Intern Med       Date:  2020-01-14       Impact factor: 25.391

Review 10.  Personalized Management of Type 2 Diabetes.

Authors:  Patricia R Peter; Beatrice C Lupsa
Journal:  Curr Diab Rep       Date:  2019-11-04       Impact factor: 4.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.